EGFR and non-small cell lung carcinoma: The results revealed that regardless of the pattern of treatment for NSCLC patients with wild-type EGFR, no significant difference existed between the two groups (HR = 0.92, 95% CI: 0.69–1.23, P = 0.574) (Fig. 6B).